Covalent inhibitors of the common mutant isoform of RAS, KRAS(G12C), have begun to unlock the potential of targeting RAS oncoproteins, but limitations to this approach remain. Now, two papers ...
RAS(ON) Inhibitor Combination Studies: RMC-6236 with Pembrolizumab: RMC-LUNG-101B is an arm of the Phase 1b study of RMC-6236 in combination with pembrolizumab, with or without chemotherapy, in ...
Revolution Medicines (RVMD) announced encouraging antitumor activity and safety/tolerability data for RMC-6236, its RAS multi-selective inhibitor, in patients with previously treated pancreatic ductal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results